19/09/02
20070057446

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/76604 A1

(51) International Patent Classification[7]: A61K 31/4965

(21) International Application Number: PCT/KR01/00319

(22) International Filing Date: 2 March 2001 (02.03.2001)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
2000/18134 7 April 2000 (07.04.2000) KR

(71) Applicant and
(72) Inventor: **KIM, Sang, Geon** [KR/KR]; Gangchon Apt. 101-504, Ichon 1-dong, Youngsan-ku, Seoul 140-727 (KR).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **KANG, Keon, Wook** [KR/KR]; 504-1 Gilm 3-dong, Seongbuk-ku, Seoul 136-113 (KR).

(74) Agent: **LEE, Kuiy, Dong**; Seoul Building, 114-31 Unidong, Chongro-ku, Seoul 110-350 (KR).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

[Continued on next page]

(54) **Title:** PROPHYLACTIC AND THERAPEUTIC USE OF OLTIPRAZ AS AN ANTIFIBROTIC AND ANTICIRRHOTIC AGENT IN THE LIVER AND PHARMACEUTICAL COMPOSITION CONTAINING OLTIPRAZ



(57) **Abstract:** The present invention provides a prophylactic and therapeutic use of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) as an antifibrotic and anticirrhotic agent in the liver and a pharmaceutical composition containing oltipraz for treating and preventing hepatic fibrosis and cirrhosis. Oltipraz of the invention can be used as a medicine optionally with other drugs for treating and preventing hepatic fibrosis and cirrhosis and shows an inhibiting effect of hepatic fibrosis at a relatively low dosage. Formulations using an optimal dose of oltipraz, which is provided by the invention, have a surprisingly good effect on the treatment and prevention of hepatic fibrosis and cirrhosis and are safe drugs that have a low toxicity on the human body.

WO 01/76604 A1

162162

ACTION